| abstract |
A therapeutic drug for cancer according to the invention is characterized by comprising the following Compound A or a pharmaceutically acceptable salt thereof and the following Compound B or a pharmaceutically acceptable salt thereof in combination; Compound A: Compound A1 represented by the following general formula (1) or a water-soluble prodrug A2 thereof; Compound B: At least one compound selected from the group consisting of a platinum anticancer compound, a gemcitabine compound, a 5-FU compound, a taxane compound, a vinca alkaloid compound, an anticancer tyrosine kinase inhibitory compound and an anticancer monoclonal antibody. (1) In the formula, R11 represents a hydrogen atom, a halogen atom or a C1-C6 alkyl group; R12 represents a hydrogen atom, a halogen atom, a C1-C6 alkyl group or a hydroxyl group; R21 represents a hydrogen atom or a C1-C10 alkyl group which may have 1 to 3 substituents; R22 represents a hydrogen atom, an amino group, a C1-C6 alkyl group which may have 1 to 3 substituents, a C1-C6 alkoxy group, a C1-C6 alkylthio group, a mono C1-C6 alkylamino group or a di C1-C6 alkylamino group. |